Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands				1 Months Ended	3 Months Ended			9 Months Ended
	Oct. 16, 2024	Oct. 07, 2024	Aug. 26, 2024	May 31, 2023 USD ($)	Dec. 31, 2024 USD ($)	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2024 USD ($) reportable_segment	Dec. 31, 2023 USD ($)	Oct. 29, 2024 independent_director	Mar. 31, 2024 USD ($)
Concentration Risk [Line Items]
Previous number of reporting segments | reportable_segment								2
Number of reporting segments | reportable_segment								1
Reverse stock split	0.05	0.05
% of Revenue								100.00%	100.00%
Restricted cash					$ 13,900			$ 13,900			$ 8,400
Decrease in escrow deposit				$ 6,000		$ 6,200
Accumulated deficit					2,354,626			2,354,626			2,173,088
Cash and cash equivalents					$ 79,350		$ 242,418	$ 79,350	$ 242,418		$ 216,488
Reduction in force (as a percent)					40.00%
Percentage of total voting power of outstanding stock			67.00%
Number of independent directors appointed | independent_director										3
Minimum
Concentration Risk [Line Items]
Reverse stock split			0.200
Maximum
Concentration Risk [Line Items]
Reverse stock split			0.0333
Microarrays | Cost of Goods and Service, Product and Service Benchmark | Supplier Concentration Risk
Concentration Risk [Line Items]
% of Revenue					100.00%		100.00%	100.00%	100.00%
K I T S | Cost of Goods and Service, Product and Service Benchmark | Supplier Concentration Risk
Concentration Risk [Line Items]
% of Revenue					100.00%		100.00%	100.00%	100.00%
Laboratory Services | Cost of Goods and Service, Product and Service Benchmark | Supplier Concentration Risk
Concentration Risk [Line Items]
% of Revenue					100.00%		100.00%